Barry Brown - VTv Therapeutics Chief Officer
| VTVT Stock | USD 14.18 0.65 4.38% |
Insider
Barry Brown is Chief Officer of vTv Therapeutics
| Age | 63 |
| Address | 3980 Premier Drive, High Point, NC, United States, 27265 |
| Phone | 336 841 0300 |
| Web | https://vtvtherapeutics.com |
VTv Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4148) % which means that it has lost $0.4148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6213) %, meaning that it created substantial loss on money invested by shareholders. VTv Therapeutics' management efficiency ratios could be used to measure how well VTv Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.93 in 2024. Return On Capital Employed is likely to gain to -60.72 in 2024. At this time, VTv Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 23.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 10.5 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Bradley JD | Lumos Pharma | 45 | |
| James JD | Eliem Therapeutics | 58 | |
| Peter Rhode | HCW Biologics | 66 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| BBA CPA | Lumos Pharma | 57 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| David MBA | Seres Therapeutics | 63 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Hing Wong | HCW Biologics | 70 | |
| MD BA | Lumos Pharma | 69 | |
| Lori CPA | Lumos Pharma | 40 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Carl Langren | Lumos Pharma | 69 | |
Management Performance
| Return On Equity | -3.62 | ||||
| Return On Asset | -0.41 |
vTv Therapeutics Leadership Team
Elected by the shareholders, the VTv Therapeutics' board of directors comprises two types of representatives: VTv Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VTv. The board's role is to monitor VTv Therapeutics' management team and ensure that shareholders' interests are well served. VTv Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VTv Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David III, Sr Counsel | ||
| Vanessa McDade, Chief Officer | ||
| Elizabeth Keiley, Executive Counsel | ||
| Carmen Valcarce, Chief VP | ||
| Paul MSc, President CEO | ||
| Steven MBA, Executive CFO | ||
| MD FACC, Executive Chairperson | ||
| Richard Nelson, Executive Director | ||
| Thomas MD, Chief Officer | ||
| MSc MSc, Pres CEO | ||
| Barry Brown, Chief Officer |
VTv Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VTv Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.62 | ||||
| Return On Asset | -0.41 | ||||
| Operating Margin | (22.86) % | ||||
| Current Valuation | (4.32 M) | ||||
| Shares Outstanding | 2.61 M | ||||
| Shares Owned By Insiders | 38.82 % | ||||
| Shares Owned By Institutions | 14.95 % | ||||
| Number Of Shares Shorted | 28.85 K | ||||
| Price To Earning | (4.19) X | ||||
| Price To Book | 2.47 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.